Study guide

5.4 Neuromuscular Blockade in Critical Illness

Board Certified Critical Care Pharmacist Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pathophysiology and Recognition of Critical Illness

1.1 Pathophysiology of Shock and Sepsis 1.2 Respiratory Failure and ARDS Pathophysiology 1.3 ICU-Acquired Weakness and Post-Intensive Care Syndrome 1.4 Chronic Disease States and Risk Factors for Critical Illness

2 Chapter 2: Medical Devices and Circulatory Support

2.1 Hemodynamic Monitoring and Interpretation 2.2 Mechanical Circulatory Support 2.3 Mechanical Ventilation Modes and Settings 2.4 Continuous Renal Replacement Therapy 2.5 Lines, Tubes, and Drains in Critical Care

3 Chapter 3: Fluid, Electrolyte, and Acid-Base Management

3.1 Resuscitation Fluids: Crystalloids vs. Colloids 3.2 Electrolyte Disorders in the ICU 3.3 Acid-Base Disorders and Interpretation

4 Chapter 4: Vasoactive and Inotropic Therapy in Shock

4.1 Vasopressors in Distributive Shock 4.2 Inotropes and Vasopressors in Cardiogenic and Obstructive Shock

5 Chapter 5: Sedation, Analgesia, and Delirium (PADIS)

5.1 Pain and Analgesia in the ICU 5.2 Sedation Strategies and Medication Selection 5.3 Delirium Assessment, Prevention, and Treatment 5.4 Neuromuscular Blockade in Critical Illness

6 Chapter 6: Cardiovascular Emergencies

6.1 Acute Coronary Syndromes in ICU Patients 6.2 Acute Decompensated Heart Failure 6.3 Hypertensive Emergencies and Arrhythmias

7 Chapter 7: Pulmonary and Infectious Diseases in the ICU

7.1 Severe Sepsis and Septic Shock Antimicrobial Selection 7.2 Pharmacotherapy for Mechanical Ventilation and ARDS 7.3 Severe Infections in the ICU

8 Chapter 8: Neurocritical Care

8.1 Ischemic and Hemorrhagic Stroke Management 8.2 Intracranial Hypertension and Brain Edema 8.3 Status Epilepticus and Sedation in Brain Injury

9 Chapter 9: Toxicology, Endocrine, and Hematologic Emergencies

9.1 Toxicology and Antidote Therapy in the ICU 9.2 Endocrine Emergencies 9.3 Hematologic Emergencies, Anticoagulant Reversal, and Transfusions 9.4 Gastrointestinal and Hepatic Emergencies in the ICU 9.5 Dermatologic and Immunologic Conditions in the ICU 9.6 Trauma, Burns, Supportive Care, and End-of-Life Pharmacotherapy

10 Chapter 10: Special Populations, Pharmacokinetics, and Nutrition

10.1 Altered Pharmacokinetics in Critically Ill Patients 10.2 Therapeutic Drug Monitoring in the ICU 10.3 Nutrition Support: Enteral vs. Parenteral

11 Chapter 11: Quality, Safety, and Clinical Guidelines

11.1 Medication Safety and Error Prevention in the ICU 11.2 Antimicrobial Stewardship and Infection Prevention 11.3 Implementation of Clinical Practice Guidelines 11.4 Healthcare Regulations, Standards, and Drug Interactions

12 Chapter 12: Practice Management, Biostatistics, and Evidence-Based Medicine

12.1 ICU Formulary Management and Cost-Effectiveness 12.2 Biostatistics and Literature Evaluation 12.3 Clinical Trial Interpretation in Critical Care 12.4 Professional Development, Precepting, and ICU Pharmacy Services 12.5 Alternative ICU Delivery Models and Disaster Healthcare Management

13 Chapter 13: Treatment Planning and Care Coordination

13.1 Goals of Care, Perioperative Care, and Transitions of Care 13.2 Medication Delivery Routes and Devices in Critical Illness 13.3 Social Determinants of Health and Patient/Caregiver Education

5.4 Neuromuscular Blockade in Critical Illness

Key Takeaways Explain This Topic AI

Neuromuscular blocking agents (NMBAs) paralyze skeletal muscle but provide NO sedation, amnesia, or analgesia; deep sedation is mandatory.

Routine use of continuous NMBAs in ARDS is no longer recommended; they are reserved for early, severe ARDS with persistent ventilator dyssynchrony despite optimized sedation.

Train-of-Four (TOF) monitoring is used to titrate NMBA infusions to the minimum effective dose, typically targeting 1-2 twitches.

ICU-acquired weakness (ICUAW) is a major complication of NMBA use, often exacerbated by concomitant corticosteroid administration.

Last updated: July 2026

Neuromuscular Blockade in Critical Illness

Neuromuscular blocking agents (NMBAs) induce skeletal muscle paralysis. In the ICU, they are primarily used to facilitate mechanical ventilation in patients with severe respiratory failure, manage elevated intracranial pressure, or treat severe muscle spasms (e.g., tetanus). Because of significant potential for harm, their use requires strict protocols and monitoring.

The Golden Rule of NMBAs

NMBAs provide ZERO sedation, amnesia, or analgesia.

Administering a paralytic to an awake or inadequately sedated patient causes terrifying psychological trauma and distress. Therefore, before initiating an NMBA, the patient must be deeply sedated (RASS -4 to -5) and adequately treated for pain. Sedation and analgesia must be continued without interruption throughout the duration of paralysis.

  • Indications in the ICU
  • Acute Respiratory Distress Syndrome (ARDS)

Historically, continuous NMBA infusions were routinely used in early, severe ARDS based on earlier trials. However, the subsequent ROSE trial demonstrated that routine early NMBA use did not improve mortality compared to a strategy of deep sedation alone, but did increase adverse events.

Currently, guidelines recommend against the routine use of continuous NMBAs in ARDS. Instead, they should be reserved for patients with severe ARDS (PaO2/FiO2 < 150) who exhibit persistent ventilator dyssynchrony (e.g., "fighting the ventilator," double-triggering) despite optimized sedation, analgesia, and ventilator settings.

Other indications include:

Shivering control during targeted temperature management (therapeutic hypothermia).

Status asthmaticus refractory to standard therapy.

Open abdomen to facilitate closure (in specific surgical contexts).

Pharmacology of NMBAs

NMBAs are divided into depolarizing and non-depolarizing agents.

Succinylcholine is a depolarizing agent with a very rapid onset and short duration (5-10 mins). It is used exclusively for rapid sequence intubation (RSI). It is contraindicated in hyperkalemia, major burns, crush injuries, and significant neuromuscular disease due to the risk of life-threatening hyperkalemia.

Non-depolarizing agents are used for continuous infusions in the ICU. They act as competitive antagonists at the nicotinic acetylcholine receptor.

Agent Elimination Clinical Considerations

Cisatracurium Hofmann elimination (organ-independent) The preferred agent for continuous infusion in patients with renal or hepatic impairment. Does not cause histamine release.

Rocuronium Hepatic (primary), Renal (secondary) Can accumulate in hepatic or severe renal dysfunction, leading to prolonged paralysis. Faster onset than cisatracurium.

Vecuronium Hepatic (primary), Renal (secondary) Has an active metabolite that accumulates in renal failure. Prolonged recovery times are common after continuous infusion.

Monitoring: Train-of-Four (TOF)

When a continuous NMBA infusion is utilized, the dose must be titrated to the minimum effective level to achieve the clinical goal (e.g., ventilator synchrony) while minimizing toxicity. This is achieved using peripheral nerve stimulation, most commonly the Train-of-Four (TOF).

How TOF Works:

Two electrodes are placed over a peripheral nerve, typically the ulnar nerve (causing thumb adduction) or the facial nerve (causing eyebrow twitch).

The device delivers four consecutive electrical stimuli.

The clinician observes or palpates the number of muscle twitches.

Interpretation:

4/4 twitches: 0-75% receptor blockade (insufficient paralysis).

1 to 2/4 twitches: 85-90% receptor blockade (optimal therapeutic range for most ICU indications).

0/4 twitches: 100% receptor blockade (overshoot; the dose should be reduced as the patient is over-paralyzed).

Crucial Point: TOF should always be used in conjunction with clinical assessment. If a patient has 3 twitches but is perfectly synchronous with the ventilator and meeting oxygenation goals, the NMBA dose does not necessarily need to be increased.

Complications of NMBAs

ICU-Acquired Weakness (ICUAW): Prolonged use of NMBAs increases the risk of severe, long-lasting muscle weakness. This risk is synergistically increased when NMBAs are administered concurrently with systemic corticosteroids.

Masking of Seizures: NMBAs paralyze motor function but do not stop brain activity. An EEG is required if status epilepticus is suspected.

Corneal Abrasions: Paralyzed patients cannot blink. Eye care with lubricating drops and taping the eyes shut is essential.

Venous Thromboembolism (VTE) and Pressure Ulcers: Due to complete immobility, rigorous DVT prophylaxis and frequent repositioning are required.

Clinical Scenario

A 60-year-old male with severe ARDS is intubated. Despite receiving continuous infusions of fentanyl and propofol, achieving a RASS of -4, he continues to double-trigger the ventilator, causing dangerous spikes in his airway pressures. The critical care physician decides to initiate a continuous infusion of cisatracurium.

Discussion: The initiation of an NMBA is appropriate here because the patient has refractory ventilator dyssynchrony despite deep sedation. Cisatracurium is a logical choice, especially if the patient has underlying organ dysfunction. The pharmacist must ensure that the propofol and fentanyl infusions are maintained throughout the paralysis. The nurse will initiate TOF monitoring, titrating the cisatracurium to a goal of 1-2 twitches while ensuring the patient's airway pressures stabilize.